Check the appropriate box:

     ☐          

Preliminary Proxy Statement

☐    

CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E)(2))

☐    

Definitive Proxy Statement

☑    

Definitive Additional Materials

☐    

Soliciting Material Pursuant to Section 240.14a-12

Payment of filing fee (check the appropriate box):

     ☑          

No fee required.

☐    

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11

(1) 

Title of each class of securities to which transaction applies:

(2) 

Aggregate number of securities to which transaction applies:

(3) 

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) 

Proposed maximum aggregate value of transaction:

(5) 

Total fee paid:

☐    

Fee paid previously with preliminary materials.

☐    

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the  offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule  and the date of its filing.

(1) 

Amount Previously Paid:

(2) 

Form, Schedule or Registration Statement No.:

(3) 

Filing Party:

(4) 

Date Filed:

We progressed important product candidates in all six of our therapeutic areas and delivered on our annual priorities to execute critical product launches and long-term commercial objectives.

Our deep experience in biologics development and capabilities in biotechnology manufacturing positions us for success in the emerging biosimilars market and, in 2017, we significantly advanced our biosimilars portfolio. We currently have two biosimilars approved by the FDA and the EMA (AMJEVITA™/AMGEVITA™ (biosimilar adalimumab (HUMIRA^®) and MVASI™ (biosimilar bevacizumab (Avastin^®)), one biosimilar under FDA and EMA regulatory review (ABP 980 (biosimilar trastuzumab (Herceptin^®)), and two biosimilar candidates in Phase 3 (ABP 710 (biosimilar infliximab (REMICADE^®)) and ABP 798 (biosimilar rituximab (RITUXAN^®))).

We secured 80 country/product launches of new medicines in new indications around the world and our medicines are now available to patients in approximately 100 countries worldwide.

We invested in next-generation biomanufacturing that dramatically reduces the scale and costs of making biologics while maintaining a reliable, high-quality, compliant supply of medicines. In 2017, our new Singapore facility that utilizes next-generation biomanufacturing was approved for certain commercial scale production by multiple regulatory agencies, including the U.S. Food and Drug Administration, or FDA, and the European Medicines Agency, or EMA. In early 2018, we announced that we will invest in greater manufacturing capacity to support the volume growth that we foresee and, as a result, plan to build a new drug substance manufacturing plant using our next-generation biomanufacturing capability in the U.S. which will add highly skilled jobs here in the U.S.

We have built leading patient- and provider-friendly device capabilities to enhance patient experience and to differentiate our products. Notably, in 2017, we launched the Enbrel Mini™ single-dose prefilled cartridge with AutoTouch™ reusable auto-injector. Meanwhile, the Neulasta^® Onpro^® kit continued to grow share and by the end of 2017 represented approximately 60% of Neulasta sales in the U.S.

Our strong cash flows and balance sheet (along with our successful execution of our transformation efforts) allowed continued investment for long-term growth through internal research and development (investing $3.6 billion in 2017) and external business development transactions, while simultaneously returning $6.5 billion of capital to our stockholders.

We continue to improve our business and operating model through significant transformation and process improvement efforts. Between 2014 and 2017, we have realized approximately $1.5 billion of transformation and process improvement savings that were reinvested in product launches, clinical programs and external business development.

Our one-year total shareholder return, or TSR, of 22% and our five-year TSR of 125% outperformed the one- and five-year average TSR of our peer group of 10% and 101%, respectively.

As referenced above, we returned $6.5 billion of capital to our stockholders in the form of dividends ($3.4 billion) and stock repurchases ($3.1 billion). Further, we increased our quarterly dividend per share 15% over 2016 (to $1.15 per share for 2017). This year, based on our confidence in the long-term outlook for our business, enhanced by the Tax Cuts and Jobs Act, and consistent with our ongoing objective to return capital to our stockholders, we executed a tender offer for $10 billion in shares.

We pay for performance, and pay outcomes reflect the achievements of our Named Executive Officers, or NEOs, against our short- and long-term performance.

Compensation is performance-based and, as a consequence, ~69% of our other NEOs’ 2017 target direct compensation and ~75% of my target direct compensation was based solely on our Company’s performance (paid in the form of annual cash incentive awards based on our annual Company performance goals, stock options, and performance units to be paid based on the Company’s performance over a three-year performance period). We use median values as the reference point for each element of compensation at all levels, including our NEOs.

Our compensation program is directly linked to our performance and strategy. Each year, our Compensation and Management Development Committee approves Company performance goals that are designed to focus our staff members on delivering our financial and operational objectives to drive annual performance, advance strategic priorities, and position us for longer-term success.

A substantial majority of compensation is performance-based, including 80% performance-based long-term incentive equity award grants, for our NEOs.

A clawback policy and our incentive cash compensation plans contain recoupment provisions.

Robust stock ownership and retention guidelines.

We have a highly-engaged, experienced and independent Board; 12 of the 13 director nominees are independent and we are committed to Board refreshment with an average tenure of ~4.8 years for our director nominees.

We have a lead independent director role with substantial and specific duties, and the independent directors have elected Robert A. Eckert to serve as the lead independent director for a third term.

We have a long-standing practice of stockholder engagement, and in addition to outreach to investors by our executives and our Investors Relations department, we have engaged in governance-focused outreach activities and discussions with stockholders who hold approximately 52% of our outstanding shares since our 2017 annual meeting of stockholders.

We already provide public disclosure regarding the factors that are integrated into our incentive compensation policies and the risks related to compensation.

The proposal’s underlying subject matter is our drug pricing and capital allocation decisions. Such decisions are integral to our ordinary course operations and the proposed report would put us at a competitive disadvantage and be unduly burdensome while not providing meaningful additional information to stockholders.

We remain focused on delivering breakthrough treatments for unmet medical needs and are committed to working with the entire healthcare community to ensure continued innovation and enable patient access to needed medicines. We do this by:

Investing billions of dollars annually in research and development;

Developing more affordable therapeutic choices in the form of high-quality and reliably supplied biosimilars;

Pricing our medicines to reflect the value they provide;

Partnering with payers to share risk and accountability for health outcomes;

Providing patient support and education programs and helping patients in financial need access our medicines; and

Working with policymakers, patients and other stakeholders to establish a sustainable healthcare system with access to affordable care and in which patients and their healthcare professionals are the primary decision makers.